N-of-One Selected by Admera Health to Provide Clinical Interpretation for the OncoGxOne™ 64-Gene Oncology Panel

  • Posted by Emily Haynes
  • On April 12, 2016
  • 0 Comments
LEXINGTON, Mass., April 12, 2016 – N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, today announced that Admera Health, a molecular diagnostics company focused on personalized medicine and non-invasive cancer testing, has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne™. N-of-One’s patient-specific analysis is based on the clinical and […]
Read More

Macrogen Selects N-of-One to Provide Patient-specific Interpretation for the Launch of New Clinical Next-Generation Sequencing Panels

  • Posted by Emily Haynes
  • On April 5, 2016
  • 0 Comments
LEXINGTON, Mass., April 5, 2016 – N-of-One, Inc., the leader in clinical interpretation, providing patient-specific therapeutic options for precision medicine in oncology, today announced that Macrogen Corp. has selected N-of-One to provide high-quality clinical interpretation for its newly launched clinical next-generation sequencing (NGS) panels used for cancer patients. Financial terms of the agreement are not disclosed. Macrogen […]
Read More
BACK TO
TOP
LEARN
MORE